BAY 59-3074
BAY 59-3074 Basic information
- Product Name:
- BAY 59-3074
- Synonyms:
-
- BAY 59-3074
- 3-[2-Cyano-3-(trifluoromethyl)phenoxy]phenyl4,4,4-trifluoro-1-butanesulfonicacidester
- CS-2278
- BAY-59-3074; BAY 59-3074; BAY59-3074
- BAY 59-3074;BAY-59-3074
- 1-Butanesulfonic acid, 4,4,4-trifluoro-, 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl ester
- inhibit,Cannabinoid Receptor,Bay 59-3074,Inhibitor,Bay 593074,Bay 59 3074
- Bay 59-3074, 10 mM in DMSO
- CAS:
- 406205-74-1
- MF:
- C18H13F6NO4S
- MW:
- 453.36
- Product Categories:
-
- Pharmaceutical intermediate
- Mol File:
- 406205-74-1.mol
More
Less
BAY 59-3074 Chemical Properties
- Boiling point:
- 490.6±45.0 °C(Predicted)
- Density
- 1.49±0.1 g/cm3(Predicted)
- storage temp.
- Store at +4°C
- solubility
- DMSO:56.78(Max Conc. mg/mL);135.05(Max Conc. mM)
Ethanol:68.17(Max Conc. mg/mL);162.14(Max Conc. mM) - form
- A crystalline solid
- color
- White to off-white
More
Less
BAY 59-3074 Usage And Synthesis
Uses
Bay 59-3074, is a novel cannabinoid CB1/CB2 receptor partial agonist with antihyperalgesic and antiallodynic effects.
Definition
ChEBI: 4,4,4-trifluoro-1-butanesulfonic acid is an aromatic ether.
Biological Activity
Novel CB 1 /CB 2 receptor partial agonist (K i values are 48.3 and 45.5 nM at human CB 1 and CB 2 receptors respectively). Orally active CB 1 agonist in vivo . Displays anti-hyperalgesic and antiallodynic properties in rat models of chronic neuropathic and inflammatory pain.
in vivo
BAY 59-3074 (0.3-3 mg/kg; oral administration; daily; for 2 weeks; male Wistar rats) treatment improves antihyperalgesic and antiallodynic effects against thermal or mechanical stimuli in rat models of chronic neuropathic and inflammatory pain.
| Animal Model: | Male Wistar rats (160-250 g)[1] |
| Dosage: | 0.3 mg/kg, 1 mg/kg, and 3 mg/kg |
| Administration: | Oral administration; daily; for 2 weeks. |
| Result: | Antiallodynic efficacy in the spared nerve injury model was maintained after 2 weeks of daily administration. Tolerance developed rapidly (within 5 days) for cannabinoid-related side effects. Antihyperalgesic and antiallodynic efficacy was maintained/increased. |
IC 50
CB1: 48.3 nM (Ki); CB2: 45.5 nM (Ki)
BAY 59-3074Supplier
Shanghai Boyle Chemical Co., Ltd.
- Tel
- sales@boylechem.com
Shanghai Boyle Chemical Co., Ltd.
- Tel
- 021-50182298 021-50180596
- sales@boylechem.com
3B Pharmachem (Wuhan) International Co.,Ltd.
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
BOC Sciences
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
Haoyuan Chemexpress Co., Ltd.
- Tel
- 021-58950125
- info@chemexpress.com